It was therefore concluded that BCL3 mediates both HDAC-1 protein expression, as well as interrupting the interaction of HDAC-1 with β-catenin, resulting in aberrant acetylation of β-catenin and the consequent activation of β-catenin/TCF-mediated transcription, within CRC cells. The gene discussed is BCL3; the disease is colorectal carcinoma.